Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.41 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7861905 | 0.96 | ALDH1A1 (0.44) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL26519 | 0.91 | CYP1A2 (0.42) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5387718 | 0.79 | HDAC3 (0.33) | — | |
| SCHEMBL14459065 | 0.78 | HSD11B1 (0.56) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL7865257 | 0.78 | HSD11B1 (0.56) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5441916 | 0.75 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5456118 | 0.75 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL7403691 | 0.75 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5443318 | 0.75 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5441518 | 0.75 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423169-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2008-09-09 | — | — | US | claimed |
| WO-2008011016-A2 | TREATING GASTROESOPHAGEAL REFLUX DISEASE WITH 5-HT3- AND GABA RECEPTOR AGONISTS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-7232924-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2007-06-19 | — | — | US | claimed |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2006-12-21 | — | — | US | claimed |
| EP-1554237-A4 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT INC (US) | 2006-11-02 | — | — | EP | claimed |
| CN-1675165-A | Method for synthesizing acyloxyalkyl derivatives of GABA analogs | XENOPORT INC (US) | 2005-09-28 | — | — | CN | claimed |
| EP-1554237-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | Xenoport, Inc. (US) | 2005-07-20 | — | — | EP | claimed |
| US-20040248979-A1 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-12-09 | — | — | US | claimed |
| US-20040014940-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2004-01-22 | — | — | US | claimed |
| WO-2003104184-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | claimed |
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-9238616-B2 | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | ARBOR PHARMACEUTICALS, LLC | 2015-10-29 | — | — | US | disclosed |
| US-20140135395-A1 | GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME | DEPOMED, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2003104184-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | disclosed |
| US-20030083382-A1 | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity | ARBOR PHARMACEUTICALS, LLC | 2003-05-01 | — | — | US | disclosed |
| WO-2002100392-A1 | ORALLY ADMINISTERED DOSAGE FORMS OF GABA ANALOG PRODRUGS HAVING REDUCED TOXICITY | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6310098-B1 | PROVIDING GAMMA-BUTYRIC ACID, SALT OR ANALOG WHICH BINDS AN ALPHA2DELTA SUBUNIT OF A VOLTAGE-GATED CALCIUM CHANNEL AND ADMINISTERING ABOVE COMPOUND TO A PATIENT EXPERIENCING HOT FLASHES | UNIVERSITY OF ROCHESTER | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248979-A1 | Method of treating lower urinary tract disorders | RYR2, CACNA1S, CACNA1D | CYP1A2 2011/4885ALDH1A1 987/4885USP2 691/4885 |
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | CYP1A2 135/4885ALDH1A1 298/4885USP2 1727/4885 |
| US-20040014940-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | CYP1A2 1323/4885ALDH1A1 495/4885USP2 1225/4885 |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | CYP1A2 135/4885ALDH1A1 298/4885USP2 1727/4885 |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | CYP1A2 1323/4885ALDH1A1 495/4885USP2 1225/4885 |
| US-20030083382-A1 | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity | GABRB1, GABRB2, GABRB3 | CYP1A2 75/4885ALDH1A1 37/4885USP2 2211/4885 |
| US-20140135395-A1 | GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME | GABARAPL2, GABARAPL1, GABARAP | CYP1A2 1635/4885ALDH1A1 1596/4885USP2 1104/4885 |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CYP1A2 135/4885ALDH1A1 298/4885USP2 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.